This is a retrospective study of End-Stage Kidney Disease (ESKD) patients on dialysis receiving apixaban or warfarin at Tawam Hospital \[a tertiary care hospital in Al Ain, UAE\]. The study aims to assess the appropriateness of prescribing apixaban and warfarin in this population and evaluate their safety and effectiveness.
Age range
18 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Timeframe: From date of enrollment until the date of first bleeding event or date of death from any cause, whichever came first, assessed up to 6 months
Effectiveness: VTE
Timeframe: From date of enrollment until the date of first documented VTE event or date of death from any cause, whichever came first, assessed up to 6 months
Effectiveness: Stroke
Timeframe: From date of enrollment until the date of first documented Stroke event or date of death from any cause, whichever came first, assessed up to 6 months